NCT04391283 2023-03-17
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting
First Affiliated Hospital of Zhejiang University
Unknown
Clinical Trials
5 trialsNCT05513664 2022-08-24
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Unknown
NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
NCT03532698 2020-07-23
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown